Main Navigation

Quick Links

Startup news: The latest out of J3 Bioscience, Lineage Cell Therapeutics, Myriad Genetics and SymbioCellTech

Red decorative image for "Startup News" series with multiple logos

University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:

Park City Angels announces additional investment in J3 Bioscience

J3 Bioscience logo

The Park City Angels are pleased to announce that our members have made an additional investment in J3 Bioscience. J3 Bioscience is a women’s health company focused on using its patented, proprietary technologies to create unique products, like the LivRing™, to address unmet needs for women’s vaginal health and wellness. ​

Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics

Lineage Logo

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company’s exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”). This marks the next step under the strategic collaboration announced in February 2023, under which Eterna is developing innovative engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system (CNS) diseases and other neurology indications.

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Myriad logo

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

Novel Biotherapy for Type I Diabetes Presented at This Year’s American Diabetes Association Meeting

SymbioCellTech logo

SymbioCellTech (SCT), the regenerative medicine company, has released results of a three-year Investigational New Animal Drug (INAD) study that underscore the safety, effectiveness and feasibility of using Neo-Islets(™) in treating diabetic dogs, and offering such dog owners some hope for their pets. While this version of NI therapy is specifically formulated for dogs, the promising results from this dog study have positive and important implications for upcoming human trials which will test a human formulation of Neo-Islets(™).

Oh, hello!

Contact Form